By Michael Erman and Manojna Maddipatla
(Reuters) – U.S. health officials on Tuesday authorized a second COVID-19 booster dose of the two most commonly used COVID-19 vaccines for people age 50 and older, citing data showing waning immunity and the risks posed by Omicron variants of the virus.
The U.S. Food and Drug Administration agency said the new boosters – a fourth round of shots for most vaccine recipients – of the Pfizer Inc/BioNTech SE and Moderna Inc vaccines are to be administered at least four months after the previous dose. They are intended to offer more protection against severe disease and hospitalization.
The FDA also authorized a second booster dose of the vaccines for younger people with compromised immune systems – those aged 12 and older for the Pfizer/BioNTech shot and 18 and older for Moderna’s.
The U.S. Centers for Disease Control and Prevention (CDC) backed the FDA’s authorization, recommending the additional shot, particularly for older people and those with underlying medical conditions that put them at higher risk.
The decision to offer second boosters in the United States comes as some scientists have raised concern about the highly contagious and newly predominant BA.2 Omicron subvariant, which has driven up COVID-19 cases in other countries.
“If it were my relatives, I would be sending them out to do this,” top FDA official Dr. Peter Marks said during a news conference of getting booster shots. “COVID-19 has had a really disproportional adverse effect on people 65 years of age and older and those with comorbidities.”
COVID cases in the United States have dropped sharply since a record surge in January, but have seen a small uptick over the past week, according to CDC data.
BROADER BOOSTER CAMPAIGN MAY BE NEEDED
Marks said the FDA will soon weigh the benefits of authorizing another round of boosters – perhaps specifically targeted to combat new variants of concern – to a broader population after the summer.
“There may be a need for people to get an additional booster in the fall along with a more general booster campaign, if that takes place, because we may need to shift over to a different variant coverage,” he said.
The FDA said it looked at data from a relatively small, ongoing clinical trial in Israel to help make its decision. In addition, safety data from more than 700,000 people who received second boosters in Israel revealed no new concerns, the agency said.
Scientists and officials have debated for months if and when an additional booster shot would be needed as they parsed data on how long protection from the vaccines and boosters would last.
“It’s not clear that now is the right time for people to get a fourth dose,” Dr. William Moss, executive director of the International Vaccine Access Center at the Johns Hopkins Bloomberg School of Public Health said.
If there is a surge in cases in late fall or early winter, as is typical for respiratory viruses and influenza, an additional boost may then be needed, he said. The body’s neutralizing antibodies spurred on by a fourth booster given now may decline in just a few months, he said.
It is also unclear whether young, healthy people will need a fourth shot. The study of Israeli healthcare workers cited by the FDA suggested that the fourth dose added little additional protection in the age group.
Biden administration officials have said that the U.S. government currently has enough doses of the vaccines to meet the demand for another round of booster shots in older Americans, even as funding for the U.S. pandemic response has all but run out.
They say that unless Congress approves more spending, the government will not be likely to be able to be pay for future inoculations, if they are needed, particularly if the vaccines need to be redesigned to target new variants.
Around two-thirds of fully vaccinated Americans over the age of 65 and just over half of people between the age of 50 and 64 have gotten their first booster dose so far.
(Reporting by Michael Erman in New Jersey, Manojna Maddipatla and Leroy Leo in Bengaluru, Additional reporting by Ahmed Aboulenein in Washington; Editing by Bill Berkrot)